F S&P 500
5,123.25 +41.00 (+0.81%) F Dow Jones
38,324.00 +36.00 (+0.09%) F Nasdaq
17,768.50 +201.00 (+1.14%) E-mini Russell 2000 Index Futur
1,988.70 -4.50 (-0.23%) Petróleo
83.85 +0.28 (+0.34%) Oro
2,347.50 +5.00 (+0.21%)
Cogent Biosciences, Inc. (COGT)
Fuera de horario:
Cogent Biosciences, Inc.
275 Wyman Street
3rd Floor
Waltham, MA 02451
United States
617 945 5576
https://www.cogentbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 164
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1.06M | N/D | 1976 |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 749.89k | N/D | 1975 |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 773.92k | N/D | 1975 |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 763.99k | N/D | 1980 |
| Mr. Brad Barnett | Chief Technology Officer | N/D | N/D | N/D |
| Christi Waarich | Senior Director of Investor Relations | N/D | N/D | N/D |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1980 |
| Ms. Erin Schellhammer | Chief People Officer | N/D | N/D | N/D |
| Mr. Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs | N/D | N/D | N/D |
| Brad Fell | Senior Vice President of Chemistry | N/D | N/D | N/D |
Descripción
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Cogent Biosciences, Inc. a partir del 1 de abril de 2024 es 6. Las puntuaciones principales son Auditoría: 2; Junta: 7; Derechos del accionista: 8; Compensación: 8.
